T. Rowe Price Investment Management, Inc. Centessa Pharmaceuticals PLC Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,556,023 shares of CNTA stock, worth $62.3 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,556,023
Previous 833,993
326.39%
Holding current value
$62.3 Million
Previous $7.53 Million
655.03%
% of portfolio
0.03%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CNTA
# of Institutions
108Shares Held
118MCall Options Held
5.9KPut Options Held
53K-
Medicxi Ventures Management (Jersey) LTD20MShares$350 Million66.33% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$175 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$170 Million4.42% of portfolio
-
Perceptive Advisors LLC New York, NY6.28MShares$110 Million2.62% of portfolio
-
First Light Asset Management, LLC Edina, MN5.94MShares$104 Million8.27% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.65B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...